MEDIGENE

Serial Number 88347854
606

Registration Progress

Application Filed
Mar 20, 2019
Under Examination
Mar 9, 2021
Approved for Publication
Jan 12, 2021
Published for Opposition
Jan 12, 2021
Registered

Trademark Image

MEDIGENE

Basic Information

Serial Number
88347854
Filing Date
March 20, 2019
Published for Opposition
January 12, 2021
Abandonment Date
April 11, 2022
Drawing Code
3000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Apr 11, 2022
Classes
005 042 044

Rights Holder

Medigene AG

99
Address
Lochhamer Str. 11
Planegg-Martinsried 82152
DE

Ownership History

Medigene AG

Original Applicant
99
Planegg-Martinsried DE

Medigene AG

Owner at Publication
99
Planegg-Martinsried DE

Legal Representation

Attorney
ADRIENNE L. WHITE

USPTO Deadlines

All Deadlines Cleared

All 6 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

40 events
Date Code Type Description Documents
Apr 11, 2022 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Apr 11, 2022 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Sep 15, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 14, 2021 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Sep 14, 2021 EX1G S SOU EXTENSION 1 GRANTED Loading...
Sep 7, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 7, 2021 EXT1 S SOU EXTENSION 1 FILED Loading...
Mar 9, 2021 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jan 12, 2021 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 12, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Dec 23, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Dec 3, 2020 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 3, 2020 EXPT T EXPARTE APPEAL TERMINATED Loading...
Nov 3, 2020 JURT T JURISDICTION RESTORED TO EXAMINING ATTORNEY Loading...
Sep 12, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 12, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 3, 2020 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
Aug 31, 2020 CNCF S ACTION CONTINUING FINAL - COMPLETED Loading...
Aug 31, 2020 GECD O ACTION DENYING REQ FOR RECON E-MAILED Loading...
Aug 31, 2020 GEA1 O NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED Loading...
Aug 4, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 4, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 3, 2020 EXAF T EXPARTE APPEAL RECEIVED AT TTAB Loading...
Aug 3, 2020 JURT T JURISDICTION RESTORED TO EXAMINING ATTORNEY Loading...
Aug 3, 2020 EXPI T EX PARTE APPEAL-INSTITUTED Loading...
Aug 3, 2020 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
Feb 3, 2020 CNFR R FINAL REFUSAL WRITTEN Loading...
Feb 3, 2020 GNFR O FINAL REFUSAL E-MAILED Loading...
Feb 3, 2020 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Dec 30, 2019 ALIE A ASSIGNED TO LIE Loading...
Dec 30, 2019 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 30, 2019 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 9, 2019 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 7, 2019 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jun 7, 2019 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jun 7, 2019 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
May 31, 2019 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 9, 2019 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Apr 7, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 23, 2019 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical and veterinary preparations, namely, cellular preparations for the treatment of tumours/neoplastic diseases, hematological tumors, more specifically leukemias or lymphomkas, solid tumors; Pharmaceutical T-cell preparations and dendritic cell preparations for the treatment of cancer and use in immunotherapy; medical compositions in the nature of pharmaceutical preparations for the treatment of hematological and solid tumors, tumor precursors; Test kits for diagnostic preparations for medical purposes for determining the type and/or existence of a tumor in a patient consisting primarily of soluble T-cell receptors; test kits for diagnostic preparations for medical purposes for determining the type and/or existence of a tumor in a patient consisting primarily of genetically modified cells; Test kits for diagnostic preparations for medical purposes for determining the type/existence of a tumor in a patient consisting of a composition of antibodies, soluble T-cell receptors and genetically modified cells; Diagnostic and therapeutic preparations for medical purposes being mixtures of therapeutically active cells in a suitable medium, in particular produced using molecular biological, biotechnological and genetic methods
First Use Anywhere: 0
First Use in Commerce: 0
Class 042
Services in molecular biology, in particular research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological and genetic methods, and in the field of screening for compounds with pharmaceutical properties; Development of test methods and test kits; Development of adoptive T cell therapy; Development of DC vaccines; Development of cellular tumour therapy; Development of tumour markers; Development of diagnostic and therapeutic antibodies
First Use Anywhere: 0
First Use in Commerce: 0
Class 044
Cell analyses in the nature of medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical and veterinary medical services, in particular extracting of blood and/or tissue samples and analysis and evaluation relating thereto; Individualized medicine in the nature of medical services; medical services specifically, development of treatment plans for the treatment of tumors and/or neoplastic diseases, hematopoietic tumors, solid tumors; physical therapy adapted for individual patients
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Design Mark
The mark consists of the wording "MEDIGENE" in stylized script, where the letter "I" is comprised of two oval shapes.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005 042 044